In the news
Takara Bio USA, Inc. (formerly Clontech Laboratories, Inc.), a wholly owned subsidiary of Takara Bio Inc., develops, manufactures, and distributes a wide range of life science research reagents under the Takara, Clontech, and Cellartis brands. To keep you up to date with the latest happenings at Takara Bio USA, we have compiled our recent announcements and press releases below.
Takara Bio’s technology enables Indiana University of Pennsylvania and Indiana Regional Medical Center to develop a faster COVID-19 test for rural communities
Date: April 1, 2021
Categories: Press release
Takara Bio Inc., is collaborating with Indiana University of Pennsylvania (IUP), and Indiana Regional Medical Center (IRMC) to enable better and faster COVID-19 testing for rural communities in the United States and around the world.
Takara Bio USA, Inc. elevates the sensitivity of scRNA-seq in its continuing mission to support the efforts of single-cell researcher
Date: January 26, 2021
Categories: Press release
Takara Bio USA, Inc. continues to provide researchers improved sensitivity and performance for single-cell analysis with the launch of our recent next-generation sequencing product, SMART-Seq Single Cell Kit.
Takara Bio licenses CRISPR genome editing technology from MilliporeSigma
Date: December 22, 2020
Categories: Announcement
Takara Bio USA, Inc. and affiliates are excited to announce that we have entered into an agreement with MilliporeSigma to license their CRISPR integration and vector technologies.
Takara Bio USA, Inc. and bioSyntagma, Inc. develop method for large-scale automated COVID-19 testing
Date: June 8, 2020
Categories: Press release
Takara Bio USA, Inc. collaborated with bioSyntagma, Inc. and their partners to develop and validate a new high-throughput method for COVID-19 testing, and are seeking an FDA Emergency Use Authorization.
Takara Bio announces completion of a new GMP facility for manufacturing gene and cell therapy products
Date: May 26, 2020
Takara Bio Inc. has completed the construction of a new facility, the Center for Gene and Cell Therapy Processing II (CGCPII) in Shiga, Japan, which has been operational since January 2020.
Namocell, Takara Bio USA and HepaTx collaborate on single cell genomics analysis for cell therapy to treat late-stage liver diseases
Date: February 20, 2020
Categories: Press release
Namocell Inc., a leading provider of single-cell sorting and dispensing platforms, entered into a collaboration with Takara Bio and HepaTx to use Namocell's Single Cell Dispensers to perform single-cell isolation on HepaTx's unique hepatocyte-like cells (iHeps) and characterize them by single-cell RNA-seq using Takara Bio's SMART-Seq technology.
Takara Bio announces launch of human iPSC-derived intestinal epithelial cells for drug discovery research
Date: November 12, 2019
Categories: Press release
Takara Bio Inc. has launched the world's first commercially available small intestinal epithelial cells derived from human induced pluripotent stem cells, jointly developed when Takara Bio received a technology transfer from a differentiation induction method to derive these cells from hiPSCs.
Ground-breaking single-cell transcriptomic study using ICELL8 technology reveals homogeneity in mono- and multi-nucleated adult cardiomyocytes
Date: September 9, 2019
Categories: Press release
Researchers from the Max Planck Institute of Heart and Lung Research are the first to apply single-cell RNA sequencing on intact, adult mouse cardiomyocytes using the ICELL8 Single-Cell System.
High-throughput surveillance study on antibiotic resistance using the automated SmartChip system
Date: May 16, 2019
Categories: Press release
Researchers at the University of Helsinki, Universidade Católica Portuguesa, CBQF, and Technische Universität Dresden, Institute of Hydrobiology, along with other collaborators have performed the first trans-Europe surveillance study on antibiotic resistance utilizing the SmartChip Real-Time PCR System.
Takara Bio submits Drug Master File to US FDA for RetroNectin GMP grade (liquid format)
Date: April 11, 2019
Categories: Press release
Takara Bio USA, Inc. announced today that its parent company, Takara Bio Inc., submitted a Drug Master File to the Food and Drug Administration for the liquid formulation of RetroNectin GMP grade on March 15, 2019.
Takara Bio USA, Inc.
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)1.3904.6880 • Japan: +81.(0)77.565.6999
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2024 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com.
